Roche Extends Tender Offer for Ventana(Genentech and Chugai and invests approxi...)

Roche's Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide.

Roche commenced operations in the U.S. over 100 years ago and these operations include research and development centers that conduct leading-edge work in advancing disease detection and treatment. Our diagnostics and pharmaceuticals businesses in the U.S. employ more than 20,000 people and generate approximately $10 billion in sales (including Genentech), accounting for about 40% of the Roche Group's global annual revenues.
For further information, please visit http://www.roche.com.

All trademarks used or mentioned in this release are protected by law.

Further information

-- All documents on the offer to Ventana's shareholders:

http://www.roche.com/info070625

Roche Group Media Relations

Phone: +41 61 688 8888 / e-mail: basel.mediaoffice@roche.com

-- Daniel Piller (Head of Roche Group Media Relations)

-- Alexander Klauser

Brunswick Group (for U.S. media)

Phone: +1 212 333 3810

-- Steve Lipin

-- Nina Devlin

MacKenzie Partners (for U.S. investors)

Phone: +1 212 929 5500

-- Larry Dennedy

-- Bob Marese

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

THIS DOCUMENT CONTAINS CERTAIN FORWARD-LOOKING STATEMENTS. THESE FORWARD- LOOKING STATEMENTS MAY BE IDENTIFIED BY WORDS SUCH AS 'BELIEVES', 'EXPECTS', 'ANTICIPATES', 'PROJECTS', 'INTENDS', 'SHOULD', 'SEEKS', 'ESTIMATES', 'FUTURE' OR SIMILAR EXPRESSIONS OR BY DISCUSSION OF, AMO
'/>"/>